Vyleesi Medicare Part D Coverage: What You Will Actually Pay in 2026

Why Most Medicare Part D Plans Exclude Vyleesi

The short answer: Medicare Part D formulary committees generally classify Vyleesi as a lifestyle drug with limited clinical differentiation from older therapies. That classification, combined with its high wholesale acquisition cost, keeps it off standard formularies in the majority of 2026 plans.

The FDA approved bremelanotide in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on two phase 3 trials (RECONNECT 1 and RECONNECT 2) enrolling a combined 1,247 participants (FDA approval label). In those trials, bremelanotide produced a statistically significant increase in satisfying sexual events (mean increase of 1.0 event per month vs. 0.7 for placebo) and a meaningful decrease in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (Kingsberg et al., Obstet Gynecol, 2019). The effect size was modest but real.

Medicare Part D plans use a tiered formulary structure governed by CMS guidelines (CMS Part D formulary guidance). Drugs for sexual dysfunction have historically faced formulary exclusion under the "Part D drugs not covered" provisions, though CMS does not categorically exclude HSDD therapies. Individual plan sponsors make the call. A 2023 analysis of Medicare Part D formulary files showed that fewer than 12% of standalone prescription drug plans listed bremelanotide in any tier (CMS formulary reference files). Plans that do include it typically place it on Tier 5 (specialty) with prior authorization requirements.

The Real Out-of-Pocket Numbers

Without formulary coverage, a Medicare Part D beneficiary pays the full negotiated price. That figure sits near $1,200 for a 30-day supply of 8 autoinjectors at most retail pharmacies.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, effective January 2025, does help patients who fill Vyleesi prescriptions regardless of formulary status (CMS IRA fact sheet). Once a beneficiary hits $2 to 000 in true out-of-pocket spending during the calendar year, catastrophic coverage kicks in and the plan pays 100% of remaining costs. For a patient paying cash price for Vyleesi alone, that threshold would be reached in roughly two months of fills. The remaining 10 months would be covered at zero cost-sharing under catastrophic coverage.

This math changes the calculus. A patient using only Vyleesi and no other specialty medications would pay $2,000 for the year rather than $14,400 at full cash price. Patients already near the $2,000 cap from other medications could reach catastrophic coverage even sooner (KFF analysis of Part D redesign).

Still, $2,000 is a significant annual expense. Several strategies can reduce it further.

How to Request a Formulary Exception

Medicare Part D regulations require plans to have an exceptions process. A patient or prescriber can request that a non-formulary drug be covered at a lower cost-sharing tier (42 CFR § 423.578). Success depends on documentation.

The prescriber must submit a coverage determination request showing that the patient tried and failed (or has a contraindication to) all formulary alternatives. For HSDD, that typically means documenting failure of flibanserin (Addyi), which is the only other FDA-approved HSDD treatment (FDA Addyi approval). The letter should also note that bremelanotide's on-demand dosing mechanism differs from flibanserin's daily oral regimen, providing a clinical rationale for the switch.

Include these elements in the exception request:

1. Diagnosis of HSDD using DSM-5 criteria with documented duration of 6 months or longer
2. Prior treatment history (flibanserin trial dates, dose, duration, reason for discontinuation)
3. A statement that no formulary alternative provides equivalent clinical benefit
4. Supporting literature, including the RECONNECT trial data showing efficacy in patients who had not responded to prior therapy (Clayton et al., J Sex Med, 2016)

Plans must respond within 72 hours for a standard request and 24 hours for an expedited request. If denied, the patient can appeal through the independent review entity within 60 days.

Manufacturer Savings Programs and Their Medicare Limitations

Palatin Technologies offers a copay savings card for commercially insured patients that can reduce out-of-pocket costs to as low as $0 for eligible fills. This program is not available to Medicare beneficiaries.

Federal anti-kickback statutes (42 U.S.C. § 1320a-7b) prohibit pharmaceutical manufacturers from offering copay assistance to patients enrolled in federal healthcare programs, including Medicare Part D (OIG advisory opinion on copay programs). The reasoning: manufacturer copay support for federally insured patients could induce utilization that increases government spending.

There is one exception. Independent charitable foundations that meet OIG guidelines can provide copay assistance to Medicare patients without violating anti-kickback rules (OIG Special Advisory Bulletin). As of May 2026, no independent foundation specifically lists bremelanotide or Vyleesi as a covered medication. The Patient Access Network Foundation and HealthWell Foundation, two of the largest such organizations, do not currently have open funds for HSDD treatments. Patients should check these programs periodically, as fund availability changes throughout the year.

Compounded Bremelanotide: The $140 Alternative

Compounding pharmacies can prepare bremelanotide in subcutaneous injection form at a fraction of the brand-name cost. Average pricing at 503B outsourcing facilities ranges from $100 to $200 per month, with a typical figure around $140 for a supply equivalent to 8 doses.

The FDA permits compounding of commercially available drugs under section 503A (individual prescriptions) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act (FDA compounding policy). 503B outsourcing facilities are registered with the FDA and subject to current Good Manufacturing Practice requirements, providing a higher quality assurance standard than traditional 503A pharmacies.

Key considerations for compounded bremelanotide:

Medicare Part D does not cover compounded medications under most circumstances. Compounded drugs are excluded from the Part D benefit unless they contain at least one ingredient that is itself a Part D-covered drug in a commercially available form (CMS Chapter 6, Part D benefits manual). Since brand-name Vyleesi is typically not on formulary, compounded bremelanotide also falls outside Part D coverage. Patients pay cash.

The trade-off is clear: $140 per month out of pocket for compounded bremelanotide ($1,680 per year) versus the $2,000 annual cap under Part D catastrophic coverage for brand-name Vyleesi. Compounded bremelanotide is actually cheaper if the $2,000 cap would not be reached through other medications alone.

Verify that any compounding pharmacy is registered as a 503B outsourcing facility on the FDA's registered outsourcing facilities list. Potency, sterility, and beyond-use dating vary between facilities.

Comparing Bremelanotide to Flibanserin on Cost and Coverage

Flibanserin (Addyi), the other FDA-approved HSDD treatment, has a different coverage and cost profile that Medicare beneficiaries should evaluate.

Flibanserin is a daily oral tablet taken at bedtime, whereas bremelanotide is an on-demand subcutaneous injection used 45 minutes before anticipated sexual activity (Jaspers et al., J Sex Med, 2016). In a network meta-analysis, both drugs showed small but statistically significant improvements over placebo in satisfying sexual events and sexual desire scores (Gao et al., J Sex Med, 2020).

Generic flibanserin became available in 2023, bringing the cash price to approximately $50 to $100 per month. Several Medicare Part D plans include generic flibanserin on Tier 3 (preferred brand) or Tier 4 formularies, making it the more accessible option for Medicare enrollees.

The clinical trade-offs matter. Flibanserin carries a boxed warning for hypotension and syncope when combined with alcohol, and patients must abstain from alcohol during treatment (FDA Addyi REMS). Bremelanotide does not carry an alcohol restriction but can cause transient nausea (40% of patients in RECONNECT trials) and skin hyperpigmentation with repeated use (Kingsberg et al., 2019). A patient who cannot tolerate flibanserin's alcohol restriction or daily dosing schedule has a documented clinical rationale for bremelanotide, which strengthens a formulary exception request.

Step-by-Step: Reducing Your Vyleesi Costs on Medicare

A practical roadmap for Medicare Part D beneficiaries seeking bremelanotide access:

Step 1: Check your specific plan's formulary. Log in to Medicare.gov's Plan Finder tool and search for bremelanotide or Vyleesi under your current plan. The small minority of plans that do cover it will show the tier, prior authorization requirements, and estimated copay.

Step 2: If not covered, file a formulary exception. Work with your prescriber to submit the documentation outlined above. The Endocrine Society's clinical practice guidelines on female sexual dysfunction support pharmacotherapy when behavioral interventions are insufficient (Endocrine Society guidelines).

Step 3: Calculate your IRA cap math. If you are already spending significantly on other Part D medications, adding brand-name Vyleesi may push you past the $2,000 out-of-pocket cap quickly, making the remaining months essentially free.

Step 4: Price compounded bremelanotide. Contact FDA-registered 503B outsourcing facilities for pricing. Compare the annual compounded cost ($1,400 to $2,400) against your projected Part D out-of-pocket under the IRA cap.

Step 5: Apply for patient assistance. Even though manufacturer copay cards are excluded for Medicare patients, periodically check independent foundations. The NeedyMeds database tracks open and closed assistance funds by drug name.

Step 6: Consider Extra Help (Low Income Subsidy). Medicare beneficiaries with limited income and resources may qualify for Extra Help, which reduces Part D premiums, deductibles, and copayments (SSA Extra Help information). Qualifying beneficiaries pay $0 to $11.20 per fill for covered drugs, though the drug must be on formulary or approved through an exception.

Off-Label and Pipeline Considerations

Bremelanotide's FDA approval is limited to premenopausal women with HSDD. Medicare coverage for off-label uses requires that the use be supported by one of CMS's recognized compendia (AHFS Drug Information, DrugDex, or Clinical Pharmacology) (CMS Benefit Policy Manual, Chapter 15).

Research into bremelanotide for postmenopausal HSDD and male sexual dysfunction is ongoing but has not yet produced the compendial support needed for off-label Medicare coverage. A phase 2 trial in postmenopausal women (NCT03033290) showed efficacy trends similar to the premenopausal population, but the data have not been incorporated into major compendia (ClinicalTrials.gov).

The Menopause Society (formerly NAMS) notes that HSDD affects approximately 8.9% of women aged 50 to 70, a population predominantly covered by Medicare (The Menopause Society position statement). The mismatch between disease prevalence in Medicare-aged women and the premenopausal-only FDA indication creates a coverage gap that affects a large patient population.

What Happens If Your Exception Is Denied

A denied formulary exception is not the end. The Medicare Part D appeals process has five levels (CMS appeals overview):

1. Redetermination by the plan (72 hours)
2. Independent Review Entity (IRE) review (7 days)
3. Administrative Law Judge hearing (90 days, if amount in controversy exceeds $205 in 2026)
4. Medicare Appeals Council review
5. Federal court review

Most cases resolve at Level 1 or Level 2. A strong appeal at the IRE level includes peer-reviewed literature, a detailed prescriber letter, and pharmacy records documenting prior therapy trials. The IRE overturns approximately 40% of Part D coverage denials that reach it.